Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat

Nadine Friedrich,Krisztina Németh,Martin Tanner,Judit Rosta,Ildikó Dobos,Orsolya Oszlács,Gábor Jancsó,Karl Messlinger,Mária Dux
DOI: https://doi.org/10.1186/s10194-024-01717-2
2024-01-20
The Journal of Headache and Pain
Abstract:Monoclonal antibodies directed against the neuropeptide calcitonin gene-related peptide (CGRP) are effective in the prevention of chronic and frequent episodic migraine. Since the antibodies do not cross the blood brain barrier, their antinociceptive effect is attributed to effects in meningeal tissues. We aimed to probe if such an antibody can be visualized within the dura mater and the trigeminal ganglia following its administration to rats and to examine if the activity of the trigeminovascular nocisensor complex is influenced by this treatment.
neurosciences,clinical neurology
What problem does this paper attempt to address?